Royalty Pharma Plc (RPRX) - Total Assets
Based on the latest financial reports, Royalty Pharma Plc (RPRX) holds total assets worth $19.82 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Royalty Pharma Plc - Total Assets Trend (2000–2025)
This chart illustrates how Royalty Pharma Plc's total assets have evolved over time, based on quarterly financial data. Also see RPRX stock market capitalisation for the company's overall valuation and market capitalisation.
Royalty Pharma Plc - Asset Composition Analysis
Current Asset Composition (December 2025)
Royalty Pharma Plc's total assets of $19.82 Billion consist of 3.2% current assets and 96.9% non-current assets. Review RPRX current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.2% |
| Accounts Receivable | $883.70 Million | 4.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $924.63 Million | 4.7% |
Asset Composition Trend (2000–2025)
This chart illustrates how Royalty Pharma Plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See RPRX live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Royalty Pharma Plc's current assets represent 3.2% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 3.2% of total assets in 2025, down from 6.2% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is goodwill at 4.7% of total assets.
Royalty Pharma Plc Competitors by Total Assets
Key competitors of Royalty Pharma Plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Royalty Pharma Plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.66 | 1.56 | 9.53 |
| Quick Ratio | 2.66 | 1.56 | 9.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $890.13 Million | $660.39 Million | $2.42 Billion |
Royalty Pharma Plc - Advanced Valuation Insights
This section examines the relationship between Royalty Pharma Plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.27 |
| Latest Market Cap to Assets Ratio | 1.32 |
| Asset Growth Rate (YoY) | 7.7% |
| Total Assets | $19.62 Billion |
| Market Capitalization | $25.92 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Royalty Pharma Plc's assets above their book value (1.32x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Royalty Pharma Plc's assets grew by 7.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Royalty Pharma Plc (2000–2025)
The table below shows the annual total assets of Royalty Pharma Plc from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $19.62 Billion | +7.67% |
| 2024-12-31 | $18.22 Billion | +11.24% |
| 2023-12-31 | $16.38 Billion | -2.57% |
| 2022-12-31 | $16.81 Billion | -4.01% |
| 2021-12-31 | $17.52 Billion | -16.97% |
| 2020-12-31 | $21.10 Billion | +69.46% |
| 2019-12-31 | $12.45 Billion | +9.50% |
| 2018-12-31 | $11.37 Billion | -0.03% |
| 2017-12-31 | $11.37 Billion | +8.51% |
| 2016-12-31 | $10.48 Billion | -3.09% |
| 2015-12-31 | $10.82 Billion | +22941.01% |
| 2014-12-31 | $46.94 Million | -40.56% |
| 2013-12-31 | $78.98 Million | +194.34% |
| 2012-12-31 | $26.83 Million | +342.48% |
| 2011-12-31 | $6.06 Million | +35.81% |
| 2010-12-31 | $4.46 Million | +50.84% |
| 2009-12-31 | $2.96 Million | -86.90% |
| 2008-12-31 | $22.60 Million | -18.10% |
| 2007-12-31 | $27.60 Million | +251.62% |
| 2006-12-31 | $7.85 Million | -55.61% |
| 2005-12-31 | $17.68 Million | +167.67% |
| 2004-12-31 | $6.61 Million | -72.51% |
| 2003-12-31 | $24.03 Million | -12.21% |
| 2002-12-31 | $27.37 Million | -25.85% |
| 2001-12-31 | $36.91 Million | -8.57% |
| 2000-12-31 | $40.37 Million | -- |
About Royalty Pharma Plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabe… Read more